Yan Degenhardt

2.4k total citations
23 papers, 1.6k citations indexed

About

Yan Degenhardt is a scholar working on Molecular Biology, Oncology and Cell Biology. According to data from OpenAlex, Yan Degenhardt has authored 23 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 12 papers in Oncology and 10 papers in Cell Biology. Recurrent topics in Yan Degenhardt's work include Microtubule and mitosis dynamics (8 papers), Cancer-related Molecular Pathways (7 papers) and Cancer Genomics and Diagnostics (5 papers). Yan Degenhardt is often cited by papers focused on Microtubule and mitosis dynamics (8 papers), Cancer-related Molecular Pathways (7 papers) and Cancer Genomics and Diagnostics (5 papers). Yan Degenhardt collaborates with scholars based in United States, United Kingdom and Singapore. Yan Degenhardt's co-authors include Thomas A. Lampkin, Saul J. Silverstein, Joel Greshock, Xiaolu Yang, Richard Wooster, Like Qu, Jun Tang, Jennifer S. Michaelson, Scott Powers and Wenge Wang and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Cell Biology and Cancer Research.

In The Last Decade

Yan Degenhardt

22 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yan Degenhardt United States 16 1.1k 663 362 223 190 23 1.6k
Yukinori Minoshima Japan 17 1.2k 1.1× 504 0.8× 331 0.9× 272 1.2× 213 1.1× 35 1.9k
Claire Crafter United Kingdom 16 918 0.8× 650 1.0× 528 1.5× 175 0.8× 361 1.9× 26 1.5k
Constadina Arvanitis United States 11 1.3k 1.2× 637 1.0× 241 0.7× 422 1.9× 139 0.7× 21 1.9k
Kwang‐Ai Won United States 6 1.2k 1.1× 890 1.3× 384 1.1× 257 1.2× 186 1.0× 7 1.7k
Pascal Peschard Canada 16 989 0.9× 366 0.6× 258 0.7× 109 0.5× 186 1.0× 16 1.4k
Mohammed M. Dar United States 19 891 0.8× 820 1.2× 465 1.3× 184 0.8× 280 1.5× 42 1.7k
Zhi-Min Yuan United States 16 938 0.8× 606 0.9× 395 1.1× 220 1.0× 66 0.3× 20 1.3k
Motoyoshi Tanaka Japan 22 919 0.8× 361 0.5× 208 0.6× 258 1.2× 244 1.3× 49 1.5k
Lars Anders United States 7 1.1k 1.0× 497 0.7× 131 0.4× 223 1.0× 306 1.6× 12 1.5k
Micaela Quarto Italy 16 1.5k 1.4× 773 1.2× 159 0.4× 318 1.4× 128 0.7× 18 1.9k

Countries citing papers authored by Yan Degenhardt

Since Specialization
Citations

This map shows the geographic impact of Yan Degenhardt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yan Degenhardt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yan Degenhardt more than expected).

Fields of papers citing papers by Yan Degenhardt

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yan Degenhardt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yan Degenhardt. The network helps show where Yan Degenhardt may publish in the future.

Co-authorship network of co-authors of Yan Degenhardt

This figure shows the co-authorship network connecting the top 25 collaborators of Yan Degenhardt. A scholar is included among the top collaborators of Yan Degenhardt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yan Degenhardt. Yan Degenhardt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Degenhardt, Yan, Jun Guan, Peter T. Morley, et al.. (2022). Abstract 6268: Discovery and characterization of the CD96 antibody GSK6097608, a high-affinity, antagonistic anti-CD96 antibody for cancer immunotherapy. Cancer Research. 82(12_Supplement). 6268–6268. 1 indexed citations
2.
Wyce, Anastasia, Yan Degenhardt, Yuchen Bai, et al.. (2014). Abstract 382: Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer. Cancer Research. 74(19_Supplement). 382–382. 1 indexed citations
3.
Wyce, Anastasia, Yan Degenhardt, Yuchen Bai, et al.. (2013). Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer. Oncotarget. 4(12). 2419–2429. 136 indexed citations
4.
Mayes, Patrick A., Yan Degenhardt, Andrew Wood, et al.. (2012). Mitogen‐activated protein kinase (MEK/ERK) inhibition sensitizes cancer cells to centromere‐associated protein E inhibition. International Journal of Cancer. 132(3). 16 indexed citations
5.
Olmos, David, Douglas S. Barker, Rohini Sharma, et al.. (2011). Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid Malignancies. Clinical Cancer Research. 17(10). 3420–3430. 134 indexed citations
6.
Jing, Junping, Joel Greshock, Joanna D. Holbrook, et al.. (2011). Comprehensive Predictive Biomarker Analysis for MEK Inhibitor GSK1120212. Molecular Cancer Therapeutics. 11(3). 720–729. 96 indexed citations
7.
Qian, Yongzhen, Emily Hua, Kheem S. Bisht, et al.. (2011). Inhibition of Polo-like kinase 1 prevents the growth of metastatic breast cancer cells in the brain. Clinical & Experimental Metastasis. 28(8). 899–908. 33 indexed citations
8.
Moy, Christopher, Muhammad Usman Aziz, Joel Greshock, et al.. (2011). Mutation and copy number detection in human cancers using a custom genotyping assay. Genomics. 98(4). 296–301.
9.
Moy, Christopher, Catherine A. Oleykowski, Ramona Plant, et al.. (2011). High Chromosome Number in hematological cancer cell lines is a Negative Predictor of Response to the inhibition of Aurora B and C by GSK1070916. Journal of Translational Medicine. 9(1). 110–110. 6 indexed citations
10.
Huang, Jia, Lin Zhang, Joel Greshock, et al.. (2011). Frequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcome. Genes Chromosomes and Cancer. 50(8). 606–618. 91 indexed citations
11.
Degenhardt, Yan, Joel Greshock, Sylvie Laquerre, et al.. (2010). Sensitivity of Cancer Cells to Plk1 Inhibitor GSK461364A Is Associated with Loss of p53 Function and Chromosome Instability. Molecular Cancer Therapeutics. 9(7). 2079–2089. 73 indexed citations
12.
Greshock, Joel, Kurtis E. Bachman, Yan Degenhardt, et al.. (2010). Molecular Target Class Is Predictive of In vitro Response Profile. Cancer Research. 70(9). 3677–3686. 100 indexed citations
13.
Degenhardt, Yan & Thomas A. Lampkin. (2010). Targeting Polo-like Kinase in Cancer Therapy. Clinical Cancer Research. 16(2). 384–389. 211 indexed citations
14.
Degenhardt, Yan, Jia Huang, Joel Greshock, et al.. (2009). Distinct MHC gene expression patterns during progression of melanoma. Genes Chromosomes and Cancer. 49(2). 144–154. 23 indexed citations
15.
Degenhardt, Yan, Richard Wooster, W. Richard McCombie, Robert Lucito, & Scott Powers. (2008). High-content analysis of cancer genome DNA alterations. Current Opinion in Genetics & Development. 18(1). 68–72. 7 indexed citations
16.
17.
Degenhardt, Yan, Katja Remlinger, Joel Greshock, et al.. (2006). Biomarker analyses of PLK isoforms in breast cancer. Cancer Research. 66. 459–459. 1 indexed citations
18.
Tang, Jun, Like Qu, Jianke Zhang, et al.. (2006). Critical role for Daxx in regulating Mdm2. Nature Cell Biology. 8(8). 855–862. 197 indexed citations
19.
Harrison, Martin, Jing Li, Yan Degenhardt, Timothy Hoey, & Scott Powers. (2004). Wip1-deficient mice are resistant to common cancer genes. Trends in Molecular Medicine. 10(8). 359–361. 47 indexed citations
20.
Degenhardt, Yan & Saul J. Silverstein. (2001). Gps2, a Protein Partner for Human Papillomavirus E6 Proteins. Journal of Virology. 75(1). 151–160. 45 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yukinori Minoshima Breakdown of academic impact, for papers by Claire Crafter Breakdown of academic impact, for papers by Constadina Arvanitis Breakdown of academic impact, for papers by Kwang‐Ai Won Breakdown of academic impact, for papers by Pascal Peschard Breakdown of academic impact, for papers by Mohammed M. Dar Breakdown of academic impact, for papers by Zhi-Min Yuan Breakdown of academic impact, for papers by Motoyoshi Tanaka Breakdown of academic impact, for papers by Lars Anders Breakdown of academic impact, for papers by Micaela Quarto
Rankless by CCL
2026